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Abstract 
Background: Ex vivo assays are usually carried out on parasite isolates collected from patients with uncomplicated 
Plasmodium falciparum malaria, from which pregnant women are usually excluded as they are often asymptomatic 
and with relatively low parasite densities. Nevertheless, P. falciparum parasites infecting pregnant women selectively 
sequester in the placenta and may have a different drug sensitivity profile compared to those infecting other patients. 
The drug sensitivity profile of P. falciparum isolates from infected pregnant women recruited in a treatment efficacy 
trial conducted in Burkina Faso was determined in an ex vivo study.
Methods: The study was conducted between October 2010 and December 2012. Plasmodium falciparum isolates 
were collected before treatment and at the time of any recurrent infection whose parasite density was at least 100/
µl. A histidine‑rich protein‑2 assay was used to assess their susceptibility to a panel of seven anti‑malarial drugs. The 
concentration of anti‑malarial drug inhibiting 50% of the parasite maturation to schizonts (IC50) for each drug was 
determined with the IC Estimator version 1.2.
Results: The prevalence of resistant isolates was 23.5% for chloroquine, 9.2% for mefloquine, 8.0% for monodeseth‑
ylamodiaquine, and 4.4% for quinine. Dihydroartemisinin, mefloquine, lumefantrine, and monodesethylamodiaquine 
had the lowest mean IC50 ranging between 1.1 and 1.5 nM respectively. The geometric mean IC50 of the tested drugs 
did not differ between chloroquine‑sensitive and resistant parasites, with the exception of quinine, for which the IC50 
was higher for chloroquine‑resistant isolates. The pairwise comparison between the IC50 of the tested drugs showed 
a positive and significant correlation between dihydroartemisinin and both mefloquine and chloroquine, between 
chloroquine and lumefantrine and between monodesethylamodiaquine and mefloquine.
Conclusion: These ex vivo results suggest that treatment with the currently available artemisinin‑based combina‑
tions is efficacious for the treatment of malaria in pregnancy in Burkina Faso.
Trial registration: ClinicalTrials.gov ID: NCT00852423
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Background
Artemisinin-based combination treatment (ACT) is rec-
ommended by the World Health Organization (WHO) 
for the treatment of uncomplicated falciparum malaria 
[1]. The combinations comprise a fast-acting artemisinin 
derivative that rapidly reduces the parasite biomass and 
gametocyte carriage [2, 3], and a slower-acting partner 
drugs that clears the remaining parasites and provides 
post-treatment prophylaxis whose duration depends on 
its pharmacokinetic properties [4–6]. The rationale for 
combining anti-malarials with different mechanisms of 
action is to prevent the development of resistance or at 
least slow down its onset [1]. Nevertheless, artemisinin-
resistant Plasmodium falciparum has emerged in west-
ern Cambodia and the bordering regions with Thailand, 
the hotspot of multidrug-resistant parasites [7–10], and 
is now reported in five countries of the Greater Mekong 
Subregion, i.e., Cambodia, Thailand, Myanmar, Vietnam, 
and Laos [11]. Artemisinin-resistant parasites could 
either spread to other regions and continents or emerge 
independently in areas of extensive artemisinin use 
[12]. Therefore, it is important to monitor ACT efficacy 
and P. falciparum sensitivity to different anti-malarials 
in endemic countries in order to timely update treat-
ment guidelines [13]. This can be done by using different 
methods, including ex vivo assays that can provide use-
ful information on the susceptibility of the local parasite 
population to different anti-malarial drugs.
Burkina Faso changed its treatment policy in 2005, 
from chloroquine monotherapy to ACT with either 
artemether-lumefantrine (AL) or amodiaquine–artesu-
nate (AS–AQ). Since the implementation of the new 
policy in 2006, several trials have shown high efficacy of 
the recommended treatments [14–16], while only one 
ex vivo assay has been carried out [17]. Ex vivo assays 
are usually done on parasite isolates from patients with 
uncomplicated falciparum malaria, mostly children in 
sub-Saharan Africa. Malaria-infected pregnant women, 
who represent an important group at risk, are usually not 
included in these assays as they are often asymptomatic 
and with relatively low parasite densities [18, 19]. How-
ever, P. falciparum parasites infecting pregnant women 
can selectively accumulate in the placenta and represent 
a distinct sub-set of parasites expressing a unique P. fal-
ciparum erythrocyte membrane protein 1 (PfEMP1) that 
binds to the host-receptor chondroitin sulphate A (CSA). 
These PfEMP1s are structurally, antigenically and func-
tionally distinct from those expressed by parasites that 
infect children and non-pregnant women [20]. In addi-
tion, some studies concluded that parasites seen on the 
blood smear of a pregnant woman may be CSA-binding 
parasites derived from the placenta, may be CD36-bind-
ing parasites circulating outside the placenta, or may be 
a mixture of the two subpopulations [21]. It was then 
hypothesized that such parasites harvested intravenously 
could have a different sensitivity profile compared to 
those from children and non-pregnant women. There-
fore, ex vivo assays were carried out on isolates collected 
from pregnant women attending antenatal clinics and 




The study was carried out at the Clinical Research Unit 
of Nanoro (CRUN), located at about 85  km from the 
capital city of Ouagadougou. Malaria is hyperendemic 
and highly seasonal, occurring between July and Decem-
ber, corresponding to the rainy season. The entomologi-
cal inoculation rate (EIR) is estimated at 50–60 infective 
bites/person/year (Diabate A, pers comm). Malaria is the 
major reason for attending health facilities, with P. falci-
parum being responsible for more than 90% of the infec-
tions [22].
Study design
This study was part of a multicentre (Burkina Faso, 
Ghana, Malawi, and Zambia) trial (ClinicalTrials.gov ID: 
NCT00852423) [23] investigating the efficacy and safety 
of four anti-malarial treatments, namely dihydroarte-
misinin–piperaquine (DHA–PQ), mefloquine-artesunate 
(MQAS), AS–AQ and AL in falciparum malaria-infected 
pregnant women. In Burkina Faso, an ex vivo study on 
the drug sensitivity of isolates from pregnant women 
was nested into the trial. Pregnant women were included 
in the trial if they fulfilled the following inclusion crite-
ria: gestation ≥16  weeks, P. falciparum mono-infection 
at any density with or without symptoms, haemoglobin 
≥7 g/dl, residence within the health facility catchment’s 
area, and willingness to deliver at the health facility. For 
the ex vivo study the inclusion was limited to women 
with a parasite density of at least 100/µl. The study proto-
col was approved by the respective ethical review boards 
(the Ethics Committee of the University Hospital of Ant-
werp, Institutional Ethic Committee of Centre Muraz 
and the National Ethic Committee) and written informed 
consent was obtained from all study participants.
Collection of field isolates
Plasmodium falciparum field isolates were collected 
at day 0 (before treatment) and at any day of recurrent 
infection during a 63-day in vivo drug efficacy follow-
up. A volume of 3–4  ml of venous blood was collected 
in heparinized tubes and transferred within 24  h to the 
laboratory for testing. Blood was centrifuged, plasma and 
buffy coat were removed, and parasitized erythrocytes 
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were washed three times with RPMI 1640 medium 
(Sigma-Aldrich, St Louis, USA) at 37°C. Field parasite 
samples with more than 1% parasitaemia were diluted 
with uninfected erythrocytes (human blood type O+) to 
avoid any influence of an inoculum effect on assay results. 
Prior to the study start, successful experiments were con-
ducted with initial parasite densities as low as 0.002%.
Drug sensitivity testing
Monodesethylamodiaquine (MDAQ), chloroquine 
diphosphate (CQ), quinine hydrochloride (QN) and 
mefloquine (MQ) were purchased from Sigma-Aldrich 
(St Louis, USA). Dihydroartemisinin (DHA) and pipe-
raquine phosphate (PiP) were donated by Sigma-Tau 
(Rome, Italy) and lumefantrine (LUM) by Novartis 
Pharma (Basel, Switzerland). The drugs stock solutions 
were prepared at a concentration of 1 mg/ml in the fol-
lowing solvents: MDAQ and CQ in distilled water, MQ 
and PiP in lactic acid, LUM in ethanol, QN and DHA in 
methanol. Multiple wells of a 96-well culture plate were 
predosed with twofold serial dilutions of each drug at 
final concentrations that ranged from 12.5 to 3.200  nM 
for CQ, 6.25–400  nM for MDAQ, 13–3.333  nM for 
QN, 0.2–64 nM for DHA, 1.2–300.2 nM for LUM, 1.6–
100  nM for PiP and 3.2–206.3  nM for MQ. For each 
sample, 200 µl aliquots of cultured parasites, prepared as 
described above, were added to each well and incubated 
at 37°C at 5% CO2 for 72 h. The culture plates were then 
frozen and stored at −20°C for up to 4 weeks.
Parasite growth inhibition was quantified using an 
enzyme-linked immunosorbent assay (ELISA) that quan-
tifies parasite histidine-rich protein-2 (HRP-2) [24]. Two 
commercially available monoclonal antibodies (Immu-
nology Consultants Laboratory, Inc, Newberg, OR, 
USA) directed against P. falciparum-specific HRP2, i.e., 
MPFM-55A and MPFG-55P, were used for the ELISA. 
Plates were pre-coated with the first monoclonal anti-
body MPFM-55A (original concentration from the man-
ufacturer was 7,200  μg/ml) diluted at a concentration 
of 1.0  μg/ml. In order to obtain complete haemolysis 
before starting the ELISA, cultured samples were diluted 
1:2 in distilled water. One-hundred microliter of each 
haemolyzed samples were added to the ELISA plate for 
1  h then washed three times with the washing solution 
(PBS  +  0.05% Tween 20, Sigma-Aldrich). The second 
antibody (MPFG-55P) was diluted at a concentration of 
0.05 µg/ml and then added (100 µl) for 1 h at room tem-
perature, washed again three times, and incubated with 
100  µl of TMB (3,3′_,5,5′-tetramethylbenzidine) chro-
mogen (Sigma-Aldrich, St Louis, USA) in the dark for 
5–10  min. After incubation the reaction was stopped 
with 50 µl of 1 M sulfuric acid. Spectrophotometric anal-
ysis was performed with an ELISA plate reader (Multis-
kan FC, plate reader) at 450 nm.
Statistical analysis
Inhibitory concentrations (IC50s) for anti-malarials were 
calculated using IC50 Estimator Version 1.2 available 
online [25]. Data were entered in Excel version 97 and 
analyzed with Stata version 10.0. Results were expressed 
as geometric mean IC50 (concentration at which 50% of 
parasite growth was inhibited) with 95% confidence inter-
vals. Pairwise comparisons were done and the Spearman 
rank-order correlation test used to determine the cor-
relation between IC50 values. For all statistical tests, the 
significance level was set at p ≤ 0.05. The threshold IC50 
for ex vivo resistance was defined as ≥100  nM for CQ, 
≥60 nM for MDAQ, ≥800 nM for QN [26], and ≥30 nM 
for MQ [27, 28].
Results
A total of 108 P. falciparum isolates were tested and 90 
(83.3%) had interpretable results for at least one of the 
study drugs (Table 1). The overall culture success rate was 
around 80% and varied little between study drugs (from 
76.8 to 83.3 %). Missing results were due to poor ex vivo 
growth or failure to achieve adequate fit on a log dose–
response curve.
Table 1 Ex vivo susceptibility of Plasmodium falciparum isolates by drug tested
Resistance threshold defined for CQ at 100 nM, QN at 800 nM, MQ at 30 nM and MDAQ at 60 nM.
* NA not applicable as the threshold is not defined yet.
Culture success rate % (n/N) Geometric Mean IC50 (nM) [95% CI] Range Resistant isolates n (%)
MDAQ 80.6 (87/108) 1.5 [1.0–2.2] 0.1 158.5 7 (8.0)
MQ 80.6 (87/108) 1.1 [0.8–1.7] 0.02 103.7 8 (9.2)
DHA 79.6 (86/108) 1.2 [0.9–1.6] 0.1 10.2 NA*
CQ 78.7 (85/108) 40.1 [28.6–58] 1.2 1060.1 20 (23.5)
LUM 78.7 (85/108) 1.4 [1.0–2.1] 0.1 97.7 NA
QN 83.3 (90/108) 34.2 [24.1–48.5] 1.9 995.5 4 (4.4)
PiP 76.8 (83/108) 5.0 [4.1–6.3] 0.5 47.9 NA
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CQ (geometric mean IC50  =  40.7  nM; 95% CI 28.6–
57.9) had the highest rate of resistant isolates (23.5%), fol-
lowed by MQ (geometric mean IC50 =  1.1  nM; 95% CI 
0.8–1.7) with 9.2%, MDAQ (geometric mean IC50 = 1.5; 
95% CI 1.0–2.2) with 8.0%, and then QN (geometric 
mean IC50 =  34.2; 95% CI 24.1–48.5) with 4.4%. DHA, 
LUM and MDAQ had a low IC50 that ranged between 1.1 
and 1.5 nM (Table 1). The geometric mean and the resist-
ance cutoff (where available) are shown in Additional file 
1: Figure S1. Most drugs were equally active against the 
CQ-sensitive and CQ-resistant isolates except for QN 
where the IC50 for CQ-resistant isolates was higher than 
that for CQ-sensitive ones, although the difference did 
not reach statistical significance (Table  2). There was a 
positive significant correlation between the sensitivity of 
DHA and both MQ and CQ, between CQ and LUM and 
between MDAQ and MQ (Table 3).
Discussion
As expected, a substantial proportion of isolates were 
resistant to CQ while for the other drugs whose sensitiv-
ity threshold is known, the prevalence of resistant iso-
lates was <10%. The prevalence of CQ-resistant (CQ-R) 
isolates in Bobo-Dioulasso, a town situated at several 
hundreds of kilometres to the southwest of Nanoro, 
was 50% in 2006 (Lea Bonkian, pers comm) and 42.1% 
in 2008–2010 [17], a slight decrease that coincided with 
the change in the national treatment policy. As the latter 
was implemented in 2006, it may be too early to detect 
a substantial decrease of CQ-R isolates, although this 
may happen. Indeed, such a decrease has been observed 
in other African countries after withdrawing CQ as first-
line treatment and hence decreasing the selective pres-
sure on the local parasite population [29–31]. In Nanoro, 
the prevalence of CQ-R isolates as well as the CQ mean 
IC50 were lower than in Bobo-Dioulasso. However, these 
may have already been lower in the past and probably 
reflect the higher drug pressure usually found in urban 
(Bobo-Dioulasso) compared to rural (Nanoro) areas. To 
make any conclusion on the trend of CQ resistance, it 
is necessary to carry out serial ex vivo studies at regular 
intervals and in the same sites.
The persistence of CQ-R P. falciparum isolates may be 
due to the continued use of CQ by the local population 
[32], maintaining the drug selective pressure, and/or the 
cross-resistance to other drugs with similar chemical 
structure. Indeed, the use of AS–AQ as one of the first-
line treatments may contribute to maintain the drug 
pressure on CQ-R parasites and could explain the high 
prevalence found in this study. Nevertheless, MDAQ 
seems to have a good activity on the local parasites, with 
only seven (8.0%) isolates with IC50 above the accepted 
threshold of resistance, indicating that AS–AQ should 
still have a reasonable efficacy in pregnant women with 
malaria. LUM, MQ and PiP are partner drugs in ACT 
and all of them had a relatively low mean IC50, the first 
two around 1  nM and the latter at 5.0  nM. In addition, 
DHA’s mean IC50 was also low, confirming earlier reports 
from other parts of Burkina Faso as well as other sub-
Saharan African countries [17, 33–35]. This suggests that 
the efficacy of both AL and AS–AQ should be good as 
most parasite isolates were sensitive to both components 
of the two ACT. The prevalence of MQ-resistant isolates 











MDAQ 1.2 (0.6–2.7) 1.4 (0.9–2.2) 0.98
MQ 0.9 (0.4–1.9) 1.2 (0.8–2.0) 0.317
DHA 1.8 (0.9–3.4) 1.1 (0.8–1.5) 0.23
CQ 487.2 (334.9–708.9) 18.9 (15.2–23.7) <0.001
LUM 2.1 (0.7–5.9) 1.3 (0.8–2.0) 0.18
QN 64.4 (29.1–142.1) 28.8 (19.4–42.7) 0.06
PiP 6.6 (4.3–10.1) 4.7 (3.6–6.1) 0.29
Table 3 Pairwise comparison between the IC50 of tested 
drugs
a Spearman’s rank-order correlation coefficient (r).
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was slightly higher than that of MDAQ, indicating that 
MQAS efficacy in vivo would probably be similar to that 
of AS–AQ. It is important to point out that the preva-
lence of P. falciparum isolates resistant to MQ was higher 
in other West African countries where ex vivo studies 
were carried out [27, 36].
PiP had a higher mean IC50 than the other partner drugs 
in currently available ACT, namely MDAQ, MQ and 
LUM. Nevertheless, the upper value of its range was lower 
and the PiP IC50 in CQ-R and CQ-S isolates was not sig-
nificantly different, indicating that although belonging to 
the same class as CQ and AQ, PiP may be much more effi-
cacious. Therefore, the combination DHA–PiP, although 
not recommended yet for the treatment of malaria in 
pregnancy, may be the most promising among currently 
available ACT. In addition, given PiP’s long elimination 
half-life, it would have the advantage of providing a long 
post-treatment prophylaxis period in which the patient 
could be protected from emerging infections.
QN, together with CQ, had one of the highest mean IC50. 
Oral QN was recommended until recently (2014) in Bur-
kina Faso for the management of uncomplicated malaria 
during pregnancy, including during the first trimester 
[37], and it is used as rescue treatment in case of ACT fail-
ure. Although just a few isolates were above the resistance 
threshold, QN IC50 was strongly associated to that of CQ 
and was much higher in CQ-R than CQ sensitive (CQ-S) 
isolates, indicating some cross-resistance. A similar associa-
tion was observed in a previous ex vivo study carried out in 
Burkina Faso in an urban area, although the mean IC50 was 
higher, possibly indicating a higher drug selective pressure 
[17]. The relative good efficacy of most of the drugs tested 
in our study is encouraging, as these drugs will rapidly clear 
the circulating parasites. This is particularly important as 
peripheral infection confers a five-fold increased risk of pla-
cental malaria [38] and can therefore have a markedly nega-
tive impact on mothers and babies [39, 40].
Conclusion
Plasmodium falciparum parasites isolated from pregnant 
women show a drug sensitivity profile comparable to that 
recently reported from Bobo-Dioulasso, Burkina Faso 
[17]. The mean IC50 values and the prevalence of isolates 
resistant to drugs for which the threshold is known were 
generally lower in Nanoro than in Bobo-Dioulasso, pos-
sibly due to the lower drug pressure in this rural area. 
Indeed, it is not possible to ascribe the observed dif-
ferences to the type of patients from which the isolates 
were collected, namely pregnant women in Nanoro and 
children in Bobo-Dioulasso. Ex vivo results indicate that 
all currently available ACT would probably have good 
efficacy among pregnant women with malaria. None-
theless, the therapeutic response is not only dependent 
on the parasite susceptibility but also on the dose given, 
the drug disposition and metabolism. Pregnancy is asso-
ciated with physiological changes that may alter the 
pharmacokinetic of treatments administered and hence 
influence the therapeutic response [41]. In vivo treatment 
efficacy will be provided by the trial in which this ex vivo 
study is nested. The drug sensitivity profile of the parasite 
population circulating in Nanoro represents the baseline 
on which to monitor the evolution of the drug sensitivity 
profile of the local parasite population.
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